— Exact Sciences Corp. (NASDAQ: EXAS) reported Q4 2019 earnings of $0.54 per share, vs. a loss of $0.35 expected.
— Total revenues were $295.6 million, vs. $283 million expected.
— Screening revenues increased 60% to $229.4 million.
— Cologuard test volume rose 63% to 477,000.
— Average Cologuard recognized revenue per test was $481.
— Average Cologuard cost per test was $123.
— Precision Oncology proforma revenue increased 14% to $119.1 million.
— FY2020 consolidated revenue is expected to be $1.61-1.64 billion.
— FY2020 Screening revenue is expected to be $1.125-1.15 billion.
— FY2020 Precision Oncology revenue is expected to be $485-495 million.
— EXAS shares gained 1.2% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings: Highlights of Bed Bath & Beyond (BBBY) Q1 report
Home furnishing retailer Bed Bath & Beyond (NASDAQ: BBBY) has reported a net loss for the first quarter of 2022 when the company’s revenues declined by 25%. Net earnings, adjusted
Mattel (MAT): Here are a few points to keep in mind if you are considering this toymaker
Shares of Mattel Inc. (NASDAQ: MAT) have gained 1% year-to-date and 6% over the past 12 months. The company delivered double-digit growth in sales and improved profitability for its most
Prologis (PLD) set for long-term gains from high e-commerce demand
The ripples of the COVID-driven e-commerce boom are being felt beyond the retail industry, and the other sectors influenced by it include transportation and real estate. The high demand for
